MedinCell S.A.
MDCLF · OTC
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | – | $9 | $4 | $7 |
| % Growth | – | 150.6% | -46.1% | – |
| Cost of Goods Sold | – | $0 | $0 | $3 |
| Gross Profit | – | $9 | $3 | $4 |
| % Margin | – | 100% | 91.3% | 58.6% |
| R&D Expenses | – | $10 | $10 | $11 |
| G&A Expenses | – | $5 | $5 | $2 |
| SG&A Expenses | – | $7 | $6 | $6 |
| Sales & Mktg Exp. | – | $2 | $1 | $1 |
| Other Operating Expenses | – | -$0 | $0 | $0 |
| Operating Expenses | – | $17 | $16 | $16 |
| Operating Income | – | -$8 | -$12 | -$10 |
| % Margin | – | -79.8% | -318.6% | -145.5% |
| Other Income/Exp. Net | – | -$7 | -$5 | $6 |
| Pre-Tax Income | – | -$14 | -$17 | -$9 |
| Tax Expense | – | $0 | $0 | -$1 |
| Net Income | – | -$15 | -$17 | -$8 |
| % Margin | – | -154.4% | -448.3% | -116.8% |
| EPS | – | -0.5 | -0.58 | -0.29 |
| % Growth | – | 13.8% | -100% | – |
| EPS Diluted | – | -0.5 | -0.58 | -0.29 |
| Weighted Avg Shares Out | – | 29 | 29 | 28 |
| Weighted Avg Shares Out Dil | – | 29 | 29 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $1 | $0 |
| Interest Expense | – | $2 | $4 | $2 |
| Depreciation & Amortization | – | $0 | $0 | $1 |
| EBITDA | – | -$7 | -$12 | -$4 |
| % Margin | – | -76.9% | -306.8% | -51.7% |